Peri-Implantitis Clinical Trial
Official title:
Comparison of Bone Immunological Biomarkers and Microbiological Parameters of Extra Short Dental Implants and Standard Dental Implants Loaded in the Posterior Mandible
Objective: This study aimed to evaluate the total amounts of tumor necrosis factor α (TNF-α),
prostaglandin E2 (PGE2), receptor activator of nuclear factor kappa B ligand (RANKL),
receptor activator of nuclear factor kappa B (RANK), and osteoprotegerin (OPG) and the
abundance of putative oral pathogens Fusobacterium nucleatum, Porphyromonas gingivalis,
Treponema denticola, Tannerella forsythia, Prevotella intermedia, and Streptococcus oralis in
extra short and standard dental implants functioning in the posterior mandible.
Methodology: The implants were divided into two groups according to their lengths: standard
(intrabony length ≥8 mm) and extra short (intrabony length ≤ 6 mm). A total of 60 implants
were researched in 30 patients. Probing depth (PD), clinical attachment level (CAL), presence
of bleeding on probing (BOP), 3-year survival rate (CSR), and bone loss (BL) were measured.
INTRODUCTION
Dental implants are usually considered an alternative treatment option to replace lost teeth
in edentulous patients. The rate of implant placement in regions more difficult to
rehabilitate has increased with the increase in the success of osseointegration and survival.
However, besides implant placement in sites with insufficient crest width and height,
treatment times and costs have also increased with the use of grafting procedures.1 Various
surgical techniques, such as vertical bone augmentation, sinus floor elevation, and nerve
transposition, have been developed for the treatment of these bone volume insufficiencies.
However, these methods are technically sensitive and can cause significant postoperative
complications. Short dental implants have been suggested as a simpler, cheaper, and faster
alternative to prevent the disadvantages of surgical techniques and for the rehabilitation of
toothless areas.2,3 A large number of randomized controlled clinical trials demonstrated that
the long-term success and survival rates of short implants were similar to those of standard
long implants.4-6 Accumulation of microbial dental plaque around the implant is the most
important cause of implant loss. If the microbial attachment is not removed, diseases such as
peri-implant mucositis and peri-implantitis may occur and result in implant loss in the long
term. Peri-implant mucositis is a reversible inflammatory reaction in the soft tissue
surrounding the implant in function. Peri-implantitis is a microbial inflammatory disease
characterized by the resorption of the supportive bone surrounding the implant in function.7
Gram-negative anaerobic bacteria predominate around the implant sites affected by the
disease. While they resemble chronic periodontal infections, they have a more complex
microbiological character.8 Predominant species around a peri-implantitis implant are red
complex (P. gingivalis, T. denticola, and T. forsythia) and orange complex bacteria (F.
nucleatum and P. intermedia) described by Socransky.9 In 1989, Apse et al. reported a fluid
around the peri-implant sulcus with properties similar to those of the gingival crevicular
fluid, and they called this fluid peri-implant crevicular fluid (PICF).10 The PICF is an
inflammatory exudate formed by osmotic pressure. Biochemical mediators in the PICF are highly
important to determine the health of tissues around the implant.11 Prostaglandins, especially
prostaglandin E2 (PGE2), are considered as a potent mediator of alveolar bone destruction in
periodontitis. A large number of studies reported an increase in PGE2 levels from healthy
state to periodontitis.12 Tumor necrosis factor α (TNF-α) is a proinflammatory cytokine
regulating the Gram-negative bacterial response. The TNF-α concentration is an indicator of
bacterial load and degree of inflammation.13 In areas where peri-implantitis is active, the
presence and activity of osteoclasts are necessary for bone destruction to occur. The
formation and activation of osteoclasts are regulated through the activation of three members
of the TNF family: receptor activator of nuclear factor kappa B ligand (RANKL), receptor
activator of nuclear factor kappa B (RANK), and osteoprotegerin (OPG). Osteoclast
differentiation and activation occur with the binding of RANKL to RANK over the surface of
osteoclasts and precursors. OPG, which is a soluble protein of TNF receptors, antagonizes
RANK-RANKL interaction and increases bone formation by inhibiting osteoclastogenesis. The
levels of proinflammatory cytokines, such as IL-1, IL-6, TNF-α, and PGE2, and RANKL/OPG
rates, which allow the determination of osteoclastic activity, change in the case of
peri-implantitis.14 The aim of this study was to evaluate the levels of TNF-α, PGE2, RANKL,
RANK, and OPG in extra short and standard dental implants functioning in the posterior
mandible. An additional aim was to investigate the levels of putative oral pathogens F.
nucleatum, P. gingivalis, T. denticola, T. forsythia, P. intermedia, and S. oralis in
submucosal biofilm samples from the studied sites.
MATERIALS AND METHODS This study was carried out by recalling individuals whose bilateral
partial tooth losses were treated with implant-supported fixed restorations and whose
implants had been functioning for at least 3 years after prosthetic rehabilitation. The study
was conducted in accordance with the ethical guidelines from the World Medical Association
Declaration of Helsinki (version 2013) (Clinical Researches Ethical Board with the 28. 09.
2016 and 2016/009 decision numbered approval).
A total of 31 patients met the inclusion criteria. One patient did not continue the study.
Further, 60 implants were researched in 30 patients (16 female and 14 male). The bilateral
regions of patients with a standard implant and an extra short implant were grouped into
two.16 Control group: Standard implant, intra-bone length ≥8 mm (30 implants) Test group:
Extra Short implant, intra-bone length ≤6 mm (30 implants)
Collection of clinical data A single calibrated examiner performed all (full-mouth and
site-specific) clinical measurements (B.K.), including probing depth (PD), clinical
attachment level (CAL), presence of bleeding on probing (BOP), 3-year survival rate (CSR),
and bone loss (BL).
The values of PD and BOP were measured from four sites of each implant (mesial, distal,
buccal, and lingual) with a Williams type (Hue Friedy, Switzerland) plastic periodontal
probe. The PD was recorded as the distance from the base of the peri-implant to the side of
the gum in millimeters. BOP was evaluated according to the presence (+) or absence (-) of
bleeding within the first 30 s following the measurement of PD.17 Control panoramic films of
all patients were taken, and differences in the marginal bone level between radiography
images after implant placement and 3 years later were evaluated. Original films and images
taken later were taken with the same angle for standardizaton.
Collection of PICF and subgingival plaque samples After the plaques and soft attachments
around the implants were removed, the implants were isolated using cotton rolls and dried
with an air spray. The PICF was collected from the mesio-buccal region of the implant using
periopaper strips (Oraflow Inc, NY, USA). Paper strips were placed 1-2 mm inside the
peri-implant sulcus and kept for 30 s. Paper strips were placed in sterile Eppendorf tubes
containing 200 µL of phosphate-buffered saline (PBS). The tubes were kept at -80°C until the
analysis day. Paper strips contaminated with saliva or blood were excluded from the sampling.
After collecting the PICF,. the supragingival plaque was carefully removed using a sterile
scaler. Implants were isolated using cotton rolls and dried with an air spray. Subgingival
plaque samples were collected from the mesio-buccal region of the implant using a sterile
plastic Gracey curette (Hu-Friedy, Switzerland) for 30 s. The samples collected were
transferred to sterile Eppendorf tubes containing 200 µL of PBS. The tubes were kept at -80°C
until the analysis day.
PICF analysis Commercial enzyme-linked immunosorbent assay kits were used for measuring the
levels of TNF-α, PGE2, RANKL, RANK, and OPG in accordance with the manufacturer's
recommendations (Elabscience Biotechnology Co., Ltd, Wuhan, China). The measuring ranges were
as follows: TNF-α, 7.81-500 pg/mL; PGE2, 31.25-2000 pg/mL; RANKL, 0.16-10 pg/mL; RANK,
0.16-10 pg/mL; and OPG, 0.16-10 pg/mL. Optical density was measured at 450 nm, and the
samples were compared with standards. Biochemical data were measured as the total amount
(pg/30 s).
Genomic DNA preparation An extraction kit was used in accordance with the manufacturer's
recommendations to purify the DNA in the collected plaque samples (GF-1 bacterial DNA
extraction kit, Vivantis, Malaysia). Standards were used for total DNA in the target
bacteria. Genomic DNA was obtained and stored at 4°C.
Real-time polymerase chain reaction Primary probes were determined to define each bacterium
and observe the proliferation curves using real-time polymerase chain reaction (PCR) (Table
1). For the DNA amplification reaction, procedures were performed with a real-time PCR system
(Roche Light Cycler 480 Instrument II, Switzerland) using a master mix (SYBR Green Master
Mix; Life Technologies, CA, USA). PCR cycles were as follows: 10 min at 95°C, 40 cycles at
95°C for 30 s and 2 min at 60°C. DNA contents were calculated using standard curves.
Statistical analysis Statistical analyses were performed with SPSS 19.0 (IBM Inc., IL, USA).
Kolmogorov-Smirnov and Shapiro-Wilk tests were used to examine whether the variables were
normally distributed. The level of significance was used as 0.05 while commenting on the
results.
While examining the differences between the groups, the independent-samples t test was used
when the variables were normally distributed.
The nonparametric Mann-Whitney U test was used when the variables were not normally
distributed. The chi-square analysis was used while examining the relationships between the
groups of nominal variables. The survival rate (CSR) was calculated according to the number
of short and standard implants placed.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05332327 -
Comparison of the Accuracy of Different Periodontal Probes for Peri-implant Pocket Registration
|
||
Enrolling by invitation |
NCT06063876 -
Experimental Peri-implant Mucositis on Implant Sites That Were Previously Treated With or Without Implantoplasty
|
N/A | |
Completed |
NCT04249024 -
Peri-implantitis, Comparing Treatments 970 nm Laser and Mucosal Flap Surgery
|
N/A | |
Withdrawn |
NCT03624257 -
Comparing Two Treatment Modalities of Peri-implantitis - Blue Laser (445 nm) and Conventional Flap Surgery
|
N/A | |
Completed |
NCT02375750 -
Treatment of Peri-implantitis Lesions by Using Biomaterial
|
N/A | |
Completed |
NCT03018795 -
Ozone Therapy as an Adjunct to the Surgical Treatment of Peri-implantitis
|
N/A | |
Completed |
NCT03157193 -
Effect of Hyaluronic Acid on Perimplantitis
|
Phase 4 | |
Enrolling by invitation |
NCT02575274 -
Peri-Implantitis Surgical Treatment an RCT Study
|
Phase 2/Phase 3 | |
Completed |
NCT04833569 -
ICG-PDT, Periimplantitis, Diabetes Mellitus
|
Phase 1 | |
Not yet recruiting |
NCT04337645 -
Resective Surgical Treatment of Peri-implantitis.
|
N/A | |
Enrolling by invitation |
NCT06033859 -
Incidence of Bleeding on Probing as an Indicator of Peri-Implant Disease Progression
|
||
Active, not recruiting |
NCT06390124 -
Reconstructive Therapy of Peri-implantitis With PDGF-BB (Gem-21)
|
Phase 4 | |
Enrolling by invitation |
NCT05675241 -
Characterizing the Inflammation Around Dental Implants
|
||
Recruiting |
NCT04983758 -
20-year Implant Survival in Periodontally Healthy and Compromised Patients
|
||
Completed |
NCT04769609 -
Reconstructive Surgical Therapy of Peri-implantitis
|
||
Completed |
NCT04874467 -
Influence of Keratinized Mucosa on Dental Implants With Mucositis
|
N/A | |
Not yet recruiting |
NCT04323540 -
Treatment of Peri-implantitis With or Without Simultaneous Soft Tissue Augmentation
|
N/A | |
Completed |
NCT05724706 -
An Evaluation of Salivary Oxidant and Antioxidant Levels in Peri-implant Health and Disease
|
||
Completed |
NCT04559841 -
Regenerative Surgical Treatment of Peri-implantitis Using Nanobone With or Without Simvastatin
|
N/A | |
Recruiting |
NCT05906810 -
Impact of Non-surgical Periodontal Therapy in the Improvement of Early Endothelial Dysfunction in Subjects With Peri-implantitis and Peri-implant Mucositis
|
N/A |